TRVI

13.4402.04%
MT

Michael Thomas Heffernan

Independent Chairman of the Board

Mr. Michael Thomas Heffernan, B.S. Pharm, R.Ph., also known as Mike, serves as Chairman at AAVantgarde Bio s.r.l. He is Independent Non-Executive Director of enGene Therapeutics Inc. (formerly known as enGene Holdings Inc.) from July 8, 2025 and serves as its Independent Chairman since July 2026. Mr. Heffernan is an Independent Chairman of the Board of Avalo Therapeutics, Inc. from March 25, 2025. Mr. Heffernan was Interim President and Chief Executive Officer of Collegium Pharmaceutical, Inc. since November 12, 2021 until May 24, 2024. He serves as Independent Director at K36 Therapeutics, Inc. He serves as Lead Independent Director at Biohaven Ltd. since September 2022. He serves as the Chairman of the Board at NMD Pharma A/S. since January 2023. He serves as Chairman at Indalo Therapeutics since December 2019. He is the Co-Founder of Avenge Bio, Inc. since 2019 and serves as its Chief Executive Officer and Director. He was Co-Founder & Independent Chairman of Collegium Pharmaceutical, Inc. since 2022 and Co-founded Collegium Pharmaceutical, Inc. in 2002 and served as its Chairman. He had been an Independent Director of Synlogic, Inc. since December 09, 2020 until February 21, 2025. He has leadership experience in the biotech and pharmaceutical industries. He served as Chairman of the Board of CARISMA Therapeutics Inc. He serves as Chairman of the Board of Indalo Therapeutics. Hehad been Independent Director at Biohaven Pharmaceutical Holding Company Ltd. since January 31, 2020 until October 03, 2022 and had been its Lead Independent Director since December 5, 2021 until October 03, 2022. He served as the President of Collegium Pharmaceutical, Inc. since October 2002 until July 2018. He was the Chief Executive Officer at Collegium Pharmaceutical, Inc. since October 2002 until July 2018 and also served as its Secretary. He has been Senior Medical Advisor to Advocacy and Medical Education Efforts at Eli Lilly and Company since January 2013. He was Co-Founder at Clinical Studies Ltd. (CSL) and served as its Chief Executive Officer and President from 1995 to 1999. He is a Proven Entrepreneur and Senior Level Executive with more than in the pharmaceutical and related healthcare industries ranging from start-ups to restructuring of a larger company. He has extensive knowledge and contacts throughout the pharmaceutical and biotechnology industry. Mr. Heffernan has worked directly with over 100 companies in the biopharmaceutical industry including consulting on the development/implementation of drug development plans, creation of Partnership relationships and development of marketing programs to launch new products. He served as Regional Manager with Eli Lilly & Company from 1993 to 1995. He served as President of Onset Dermatologics LLC until February 13, 2013 and was its Chief Executive Officer. He served as Chairman, Chief Executive Officer and President of Innovative Clinical Solutions Ltd. (alternate name PhyMatrix) from July 1999 to 2001 and served as its Co-Chief Executive Officer from April 1999 to July 1999. He also served as President of the clinical research division at PhyMatrix. At Collegium, he was Founder of Onset Therapeutics. He joined the Collegium Pharmaceutical, Inc. in 2002. He served as the Chairman of Veloxis Pharmaceuticals, Inc. until 2020. In addition, he is actively managing Avenge Bio, Inc. an Immuno-Oncology company that he co-founded in March 2019. He was the Chairman of the Board for Veloxis Pharmaceuticals A/S since April 20, 2016 until 2020 and was its Independent Director since March 2015 until 2020. He served as the Chairman of Ocata Therapeutics, Inc. (formerly Advanced Cell Technology Inc.), from October 2013 to February 10, 2016 and on the Board since April 2012 till February 2016. He was a Director of Keryx Biopharmaceuticals Inc. since June 21, 2016 until December 12, 2018. He served as Lead Independent Director at Trevi Therapeutics, Inc since September 2020 until June 2023. He has been an Independent Director of Trevi Therapeutics, Inc. since February 2017. He was an Independent Director of Akebia Therapeutics, Inc. since December 12, 2018 until June 8, 2022. He has been a Director of Collegium Pharmaceutical, Inc. since October 2003. He served as President and Chief Executive Officer of PreCision Dermatology, Inc. from 2005 to 2010. He was a Director of PreCision Dermatology, Inc. He served as a Director of Advanced Cell Technology Inc. since April 09, 2012 until February 10, 2016. He served as a Director at Critical Therapeutics Inc. He served as Director of Innovative Clinical Solutions Ltd. since February 1998, Chiesi USA, Inc. (alternative name Cornerstone Therapeutics Inc.) since October 2008 and TYRX, Inc. (formerly TyRx Pharma, Inc.) since 2002. He served on the Board of several privately held companies. He started his career at Eli Lilly and Company, where he served in numerous sales and marketing roles. He holds a B.S. Degree in Pharmacy from University of Connecticut in 1987 and is a Registered Pharmacist.

Positions